Case Study: Pfizer’s Arena acquisition – A $6.7B deal
Posted on20 Dec 2021
Tagsacquisition, acquisition in pharma, largest ever pharma deal, pfizer, Pfizer strategic deal, pharma acquisition, pharma deal, pharma strategic deal
Comments0
Pfizer will acquire Arena Pharmaceuticals for $6.7 billion to expand its pipeline of immuno-inflammatory disease drugs in development. Why Pfizer acquired Arena?... Read More
Case Insight: Natco acquires Dash Pharmaceuticals
Posted on17 Dec 2021
Comments0
NATCO Pharma, through its affiliates, is proposing to enter into an agreement to acquire Dash Pharmaceuticals LLC subject to satisfactory completion of... Read More
FDA Grants Accelerated Approval for Alzheimer’s drug Aduhelm
Posted on10 Jun 2021
Tagsaducanumab, Aduhelm, Biogen, Eisai, global pharma licensing deal, monoclonal antibody, Neurimmune, pharma deal
Comments0
USFDA approved Aduhelm (aducanumab) for the treatment of Alzheimer disease. Alzheimer’s drug Aduhelm is research molecule of Neurimmune. Neurimmune licensed its antibody... Read More
Case Study: Strategic Insight of acquisition of Constellation Pharmaceuticals by MorphoSys
Posted on03 Jun 2021
TagsConstellation Pharmaceuticals, MorphoSys AG, pharma deal, pharma strategic deal, strategic management in pharma
Comments0
MorphoSys AG, and Constellation Pharmaceuticals, Inc. announced that they have entered into a definitive agreement whereby MorphoSys will acquire Constellation for $34.00... Read More
Case Study: Pfizer acquires Amplyx Pharmaceuticals
Pfizer has bought privately held Amplyx Pharmaceuticals for an undisclosed sum, gaining experimental antifungal and antiviral treatments as the world’s attention turns... Read More
AstraZeneca – Alexion $39 billion deal
Posted on15 Dec 2020
Tagsacquisition in pharma, global pharma deals, largest ever pharma deal, monoclonal antibody, pharma deal, ravulizumab, Soliris, Ultomiris
Comments0
AstraZeneca has agreed to buy US drugmaker Alexion Pharmaceuticals for $39 billion to bolster its positions in immunology and rare diseases. Alexion... Read More
Pfizer’s Upjohn and Mylan merged business entity will be namea as Viatris
The name of the new company to be formed by the merger of Mylan and Upjohn, a division of Pfizer, will be... Read More
S. Korea’s Mediforum acquires local pharma firms C-TRI, i-World Pharm
South Korean bio-pharma company Mediforum Co. has acquired two local pharmaceutical firms C-TRI and i-World, a move that is expected to help... Read More
Alexion acquisition of Achillion: A 1 Billion Pharma Strategic Deal
Posted on21 Oct 2019
TagsAchillion, acquisition in pharma, Alexion Pharmaceuticals, global pharma deals, pharma deal, pharma strategic deal
Comments0
Achillion focuses on the development of oral small-molecule Factor D inhibitors to treat people with rare diseases affecting the ‘complement system’, such... Read More
2018 Pharma Deal: Sanofi’s agreement to buy Bioverati @ $10.9 billion
Posted on18 Dec 2018
TagsBioverati, global pharma deals, global pharma licensing deal, pharma acquisition, pharma deal, Sanofi
Comments0
Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive... Read More